MDV analyzer

Web Tool Service

MDV analyzer, a web tool featuring analyses for patient count,
treatment volume, and more with a medical database

Analyses for patient count, prescription duration, treatment volume, and more based on Japan’s largest medical database are available.
In addition to diseases and medications, the database also supports multifaceted analyses based on actual medical procedures, such as surgeries and tests.

EBM Medical Database

Data like DPC data, lab test data, and claim data sourced from medical institutions and insurers are processed into a database upon data anonymization. It is utilized by pharmaceutical companies, medical device companies, academia, and public research institutions for marketing research, clinical research, etc.

Main Features of MDV analyzer

• Patient Count Analysis
• Concomitant Medication Rankings
• Comorbidity Rankings
• Volume of Treatment and Days of Treatment Analysis
• Medication/Disease Pattern Analysis
• Patient Count (New, Continued, Switched, Dropout)
• Patient Count (Switch from, Switch to)
• National Estimate

Analysis utilizing the hospital and health insurance databases can be performed at the same time

Aside from the comparison in market share with other companies’ formulations, demand on dosage form can also be captured for drug development. In addition, market share for hospitals and general practitioners can be captured respectively when using the health insurance database.

For marketing strategy materials

With features including rapid data extraction, definitions based on know-how, and visually appealing graph design, the new continued switched dropout analysis enable the creation of flexible marketing strategy materials.

For drugs with fluctuating treatment volume, actual situation can be checked with a histogram of treatment volume per prescription.

Disease-based market share can be tracked with monthly trend analysis of multi-indication drugs, including new indications.

Useful tool for database study, development, and regulatory interactions

Comorbidity rankings can be used to clarify the actual situation of any medication that is considered as off-label use.

By using the histograms of treatment volume and duration, actual usage can be ascertained if it is in line with the package insert, resulting in the facilitation in pharmacovigilance.

Before use

• Q1. Is there a trial version for the web tool?
  Currently, the web tool is not available for trial purpose. Our representative can provide an introduction to the web tool based on your specific requirements. Please feel free to contact us.
• Q2. Can you explain how to use the web tool before implementation?
  Our representative can provide an introduction on how the web tool operates in advance. Please feel free to contact us.
• Q3. Are there any brochures that can be used for information sharing within our organization?
  We have brochures for our web tool services. Please contact us if you are interested.

About the specifications

• Q1. Are there any examples of major uses?
  Marketing: Prescription trends, market analysis, etc.
  Academia and pharmacovigilance: Exploring potential research, regulatory submission, etc.
  R&D: Field research, assessing status of drugs with similar effects to those under development, etc.
• Q2. Does the data period include the latest data?
  Maintenance is performed once a month, and the latest data becomes available after the maintenance.
• Q3. Can I disclose the data with external parties?
  It is possible. However, prior to publication, we require a third-party disclosure agreement（TPA) with our company and a review of the materials to be published.
• Q4. Can the extracted results be used for regulatory submission?
  We receive many disclosure requests every year, and the results are used not only for regulatory submissions but also during meetings with physicians.
• Q5. Are the results representative at the national level?
  The data analysis uses actual values, and some features have been implemented to allow for extrapolation, enabling you to view national-level data.
• Q6. Is there a cost for adding accounts?
  Within a single organization, there is no additional cost for using multiple accounts.
• Q7. Is it possible to use the service from home, such as during telework?
  Yes, it is possible through a VPN connection or similar means.
• Q8. Are your services available in English?
  Some of the web tools are available in English, please feel free to contact our representative for more information.

About the Hospital data

• Q1. How many of the hospitals nationwide are DPC hospitals?
  Currently, we have a coverage rate of approximately 30% of the 1,786 DPC-designated hospitals nationwide (as of December 31, 2024).
• Q2. Is the data limited to inpatient?
  We collect insurance claim data for both inpatient and outpatient visits.
• Q3. Do DPC hospitals tend to have more patients with serious condition?
  They are mainly advanced treatment hospitals, so they tend to have a higher number of patients with more severe conditions compared to clinics. However, there is also a significant number of patients in primary care areas, such as those with lifestyle-related diseases, and we receive many requests for analysis.
• Q4. Is the data representative?
  Our data covers DPC hospitals nationwide, and the age and gender distribution of patients is similar to the survey published by the Ministry of Health, Labour and Welfare regarding the patient distribution in medical institutions across Japan. Therefore, it is considered to be representative.
• Q5. What are the advantages of this data?
  Since it is the largest database in Japan with over 50 million patients, the data has been utilized in research in different fields, including intractable and rare diseases.
• Q6. How often is the data updated?
  Update is performed at the end of every month, and the data two months prior to the update will be the latest data. (For example, the data of January 2021 will be available after the update performed at the end of March 2021)
• Q7. Is the database specialized in any disease area?
  Given the large scale of the database, we are confident that we can secure a robust number of cases for research in any disease area.
• Q8. Is it possible to assess disease severity?
  The web tool does not currently include data fields for assessing disease severity. However, through a separate service, it is possible to obtain data fields that allow for the assessment of severity in certain disease areas.
• Q9. Can the data be extrapolated to a national level?
  There is a function in MDV analyzer that allows one to perform extrapolation to obtain results at the national level.
• Q10. Is it possible to track patients’ records even if they have been transferred to another hospital?
  Each DPC hospital assigns a unique hospital-specific ID to each patient. Therefore, tracking is possible for both inpatient and outpatient data within the same DPC hospital. However, tracking after transfer to another hospital is not possible.
• Q11. Is it possible to obtain data for treatments that are not eligible for insurance reimbursement, such as out-of-pocket treatments?
  Unfortunately, our database only includes medical information that is eligible for insurance reimbursement, as it is based on claim data.

About Health insurance data

• Q1. The data is sourced from how many health insurance societies?
  It is sourced from 223 health insurance societies across Japan. (As of January 2025)
• Q2. Is the data limited to outpatient?
  We collect insurance claim data for both inpatient and outpatient visits.
• Q3. Does it include health checkup data?
  Currently, health checkup data is not available.
• Q4. Can we perform analysis by combining with the hospital data?
  Although it is not possible to link the hospital data and the health insurance data, it is possible to extract data under exactly the same conditions from each database and analyze differences in trends, for example.
• Q5. Is the database specialized in any disease area?
  Since clinic data makes up 80% of the database, we are particularly strong in areas where treatment is primarily provided at clinics.
• Q6. What are the advantages of this data?
  With its high traceability, patients’ record can be traced even if they transferred to another hospital without being counted as a new patient, resulting in an outstanding advantage on creating treatment flows.
• Q7. Which type of research can use this data?
  We believe this is suitable for research that does not require elderly patient, or studies on treatments between clinics and hospitals.
• Q8. Is it possible to track patients’ records even if they have been transferred to another hospital?
  As long as a patient is affiliated with the same health insurance association, it can be tracked.
• Q9. Can the data be extrapolated to a national level?
  This response needs to be update as the extrapolication function is also working for health insurance data.
• Q10. Is it possible to obtain data for treatments that are not eligible for insurance reimbursement, such as out-of-pocket treatments?
  Unfortunately, our database only includes medical information that is eligible for insurance reimbursement, as it is based on claim data.